Syntara Limited · ASX:SNT
Syntara — Investor Presentation (October 2024)
15 slides from Syntara's investor presentation, Oct 16, 2024
Slide 1: Syntara Investor Presentation, October 2024
For personal use only ™ Gary Phillips, CEO October 2024
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Investment Highlights
Investment Highlights For personal use only Australian-founded clinical Clinical Backed by specialist Focus on first-in-class and Funded to mid-2025 with stage drug developer. stage drug developer. healthcare investors – best-in-class drugs backed near term data to drive 54% institutional. by in hou
Slide 4: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) Share Price & Volume - YTD For personal use only Share price – 14 October 2024 $0.040 Price (AUD) Market Cap A$54.9m $0.055 Proforma cash balance (30 June 2024)1 A$13.0m $0.045 Enterprise value A$27.0m $0.035 Note: 1. Proforma cash of $13.0m inclu
Slide 5: Syntara Board under new leadership and downsized
Syntara Board under new leadership and downsized Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Exp
Slide 6: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive scientific collaborations worldwide has delivered three drugs For personal use only now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncolo
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications. For personal use only Myelofibrosis • Treatment with lysyl oxidase inhibitor significantly reduced reticulin fibrosis and megakaryocyte cell number in GATA-1low mice and JAK2V617F female mice Pancreatic Cancer • SNT-5505 a
Slide 8: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 9: SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures
SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity For personal use only Study Design Endpoints Trial Outlooks • IND approved Q3 2020 • SNT-5505 has been well •
Slide 10: PXS-5505 Phase Trial (MF-101) monotherapy; Expert review
PXS-5505 Phase 2 Trial (MF-101) monotherapy; Expert review For personal use only • “PXS-5505 continues to show not only an excellent safety profile but also promising clinical activity. The effect on bone marrow fibrosis is particularly exciting for a disease like myelofibrosis, where despite numero
Slide 11: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure Study Plan For personal use only • 19 clinical trial sites Design Treatment Cohort Endpoints • Recruitment started 13 Dec 2023 I
Slide 12: Strong interest in myelofibrosis assets from strategics
Strong interest in myelofibrosis assets from strategics Target / Acquiror / / For personal use only Date of Feb-2024 June-2023 July-2022 Announcement Drug Name Pelabresib Pacritinib Momelotinib Lead Indication / Myelofibrosis Myelofibrosis Myelofibrosis Phase (Successful Phase 3 (Marketed) (FDA File
Slide 13: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets For personal use only Anticipated Upcoming Addressable market Drug Candidate Indication Phase Milestones (US$) Interim 6 month data Myelofibrosis Phase 2 ~$1 billion1 December 2024 SNT-5505 Myelodyspla
Slide 14: Recent & anticipated news flow
Recent & anticipated news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only COMPLETED COMPLETED COMPLETED COMPLETED Q4 2024 Q4 2023 Q4 2023 Q4 2023 Q3 2024 SNT-4728 iRBD / SNT-5505 Phase 2a SNT-5505 Phase 2a SNT-5505 Phase
Slide 15: Contact: Gary Phillips, CEO
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au